scholarly journals Racial and Sex Disparities in Hepatocellular Carcinoma in the USA

2020 ◽  
Vol 19 (4) ◽  
pp. 462-469
Author(s):  
Faith Ajayi ◽  
Jenny Jan ◽  
Amit G. Singal ◽  
Nicole E. Rich
Keyword(s):  
Hepatocellular Carcinoma ◽  
The Usa ◽  
Sex Disparities

Cohort Contributions to Race- and Gender-Specific Trends in the Incidence of Hepatocellular Carcinoma in the USA

2017 ◽  
Vol 42 (3) ◽  
pp. 835-840 ◽  
Author(s):  
Eliza W. Beal ◽  
Dmitry Tumin ◽  
Ali Kabir ◽  
Dimitrios Moris ◽  
Xu-Feng Zhang ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Race And Gender ◽  
The Usa ◽  
And Gender ◽  
Gender Specific

Impact of immigration in presentation and outcomes of hepatocellular carcinoma in the USA

2019 ◽  
Vol 31 (1) ◽  
pp. 24-28 ◽  
Author(s):  
Ashraf A. Ashhab ◽  
Holly Rodin ◽  
Jesse Powell ◽  
Jose D. Debes
Keyword(s):  
Hepatocellular Carcinoma ◽  
The Usa

scholarly journals Treatment of inoperable hepatocellular carcinoma with immunotherapy

2019 ◽  
Vol 12 (7) ◽  
pp. e229744 ◽  
Author(s):  
Sean P Tighe ◽  
Umair Iqbal ◽  
Christopher T Fernandes ◽  
Aijaz Ahmed
Keyword(s):  
Hepatocellular Carcinoma ◽  
Clinical Presentation ◽  
Treatment Options ◽  
Linkage To Care ◽  
Experimental Treatment ◽  
Hepatitis C Virus Infection ◽  
Chronic Liver Diseases ◽  
The Third ◽  
The Usa ◽  
High Risk Populations

In the USA, mortality associated with hepatocellular carcinoma (HCC) continues to rise. Globally, HCC is the third most common cause of cancer-related death. In early stages of HCC, hepatic resection or liver transplantation are the preferred treatment options with a high probability of recurrence-free postoperative course. However, ineffective screening of chronic liver diseases in high-risk populations, poor linkage to care and suboptimal HCC surveillance has led to increasing rates of late-stage HCC at clinical presentation or diagnosis amenable only to palliative and experimental treatment options. Our case is a 66-year-old man with chronic hepatitis C virus infection complicated by cirrhosis and inoperable HCC which was non-responsive to selective intrahepatic trans-arterial chemoembolisation by interventional radiology. Therefore, he was treated with nivolumab immunotherapy and demonstrated normalisation of previously elevated alpha-fetoprotein levels suggestive of at least a partial response to immunotherapy. No adverse events related to nivolumab immunotherapy were encountered.

scholarly journals Sex disparities in presentation and prognosis of 1110 patients with hepatocellular carcinoma

2020 ◽  
Vol 52 (4) ◽  
pp. 701-709 ◽  
Author(s):  
Nicole E. Rich ◽  
Caitlin C. Murphy ◽  
Adam C. Yopp ◽  
Jasmin Tiro ◽  
Jorge A. Marrero ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Sex Disparities

Texas Has the Highest Hepatocellular Carcinoma Incidence Rates in the USA

2020 ◽  
Author(s):  
Hashem B. El-Serag ◽  
Rebecca Sardell ◽  
Aaron P. Thrift ◽  
Fasiha Kanwal ◽  
Paige Miller
Keyword(s):  
Hepatocellular Carcinoma ◽  
Incidence Rates ◽  
The Usa

scholarly journals Epidemiologic, humanistic and economic burden of hepatocellular carcinoma in the USA: a systematic literature review

2020 ◽  
Vol 7 (3) ◽  
pp. HEP27 ◽  
Author(s):  
Abdalla Aly ◽  
Sarah Ronnebaum ◽  
Dipen Patel ◽  
Yunes Doleh ◽  
Fernando Benavente
Keyword(s):  
Quality Of Life ◽  
Hepatocellular Carcinoma ◽  
Economic Burden ◽  
Systemic Treatment ◽  
Advanced Disease ◽  
Poor Quality ◽  
Disease Stage ◽  
The Usa ◽  
Humanistic Burden

Aim: To describe the epidemiologic, humanistic and economic burdens of hepatocellular carcinoma (HCC) in the USA. Materials & methods: Studies describing the epidemiology and economic burden from national cohorts, any economic models, or any humanistic burden studies published 2008–2018 were systematically searched. Results: HCC incidence was 9.5 per 100,000 person-years in most recent data, but was ∼100-times higher among patients with hepatitis/cirrhosis. Approximately a third of patients were diagnosed with advanced disease. Patients with HCC experienced poor quality of life. Direct costs were substantial and varied based on underlying demographics, disease stage and treatment received. Between 25–77% of patients did not receive surgical, locoregional or systemic treatment. Conclusion: Better treatments are needed to extend survival and improve quality of life for patients with HCC.

scholarly journals Associations of Serum Tumor Biomarkers with Integrated Genomic and Clinical Characteristics of Hepatocellular Carcinoma

Liver Cancer ◽  
2021 ◽  
pp. 1-13
Author(s):  
Keun Soo Ahn ◽  
Daniel R. O’Brien ◽  
Yong Hoon Kim ◽  
Tae-Seok Kim ◽  
Hiroyuki Yamada ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Lens Culinaris ◽  
Acid Metabolism ◽  
The Cancer Genome Atlas ◽  
Molecular Characteristics ◽  
Genetic Profile ◽  
Vegf Signaling ◽  
The Usa ◽  
Cancer Genome Atlas ◽  
Liver Hepatocellular Carcinoma

<b><i>Introduction:</i></b> Serum α-fetoprotein (AFP), <i>Lens culinaris</i> agglutinin-reactive AFP (AFP-L3), and des-γ-carboxy­pro­thrombin (DCP) are useful biomarkers of hepatocellular carcinoma (HCC). However, associations among molecular characteristics and serum biomarkers are unclear. We analyzed RNA expression and DNA variant data from The Cancer Genome Atlas Liver Hepatocellular Carcinoma (TCGA-LIHC) to examine their associations with serum biomarker levels and clinical data. <b><i>Methods:</i></b> From 371 TCGA-LIHC patients, we selected 91 seen at 3 institutions in Korea and the USA and measured AFP, AFP-L3, and DCP from preoperatively obtained serum. We conducted an integrative clinical and molecular analysis, focusing on biomarkers, and validated the findings with the remaining 280 patients in the TCGA-LIHC cohort. <b><i>Results:</i></b> Patients were categorized into 4 subgroups: elevated AFP or AFP-L3 alone (↑AFP&amp;L3), elevated DCP alone (↑DCP), elevation of all 3 biomarkers (elevated levels of all 3 biomarkers [↑All]), and reference range values for all biomarkers (RR). <i>CTNNB1</i> variants were frequently observed in ↑DCP patients (53.8%) and RR patients (38.5%), but ↑DCP patients with a <i>CTNNB1</i> variant had worse survival than RR patients. <i>TP53</i> sequence variants were associated with ↑AFP (30.8%) and ↑DCP (30.8%). The Wnt-β-catenin signaling pathway was activated in the ↑AFP&amp;L3, whereas liver-related Wnt signaling was activated in the RR. TGF-β and VEGF signaling were activated in ↑AFP&amp;L3, whereas dysregulated bile acid and fatty acid metabolism were dominant in ↑DCP. We validated these findings by showing similar results between the test cohort and the remainder of the TCGA-LIHC cohort. <b><i>Conclusions:</i></b> Serum AFP, AFP-L3, and DCP levels can help predict variants in the genetic profile of HCC, especially for <i>TP53</i> and <i>CTNNB1</i>. These findings may facilitate development of an evidence-based approach to treatment.

Sign in / Sign up

Export Citation Format

Share Document